Televised News Report Lifts Shares of Touted Omega 3 Fatty Acids Stock Print E-mail
By Staff and Wire Reports   
Friday, 21 September 2012 19:01
icon_NewsMakersUPShares of Neptune Technologies & Bioressources (NASDAQ: NEPT) rose 6.85% and closed up +.30 to $4.68 on Friday after The Canadian TV network, CTV, broadcast a televised news segment about krill oil featuring Neptune's Chief Global Strategy Officer Dr. Tina Sampalis.
In the segment, Dr. Sampalis shed light on the key differences between krill and fish oil, emphasizing some of the advantages of krill based Omega 3 fatty acids.

Said Sampalis : "Krill, even though it has the same amount of Omega 3's as fish oil, it is better digested, a lot better absorbed and a lot better used by the body."

According to the televised report, Omega 3 fatty acids have been touted as helping with skin problems, neurological development, inflammation and lowering cholesterol. A recent Greek study that dismissed the positive effects of Omega 3s, did not include krill oil.

Prices for shares of Neptune, Amarin Corporation (NASDAQ: AMRN) and others had been affected adversely following the recent study, but analysts at Leerink Swann reiterated an "outperform" rating on shares of Amarin, maintaining their $27 price target in a research note to investors.

According to the note, Amarin's management continues to believe the firm's FDA approved Vascepa has a decent chance of obtaining exclusivity on their new chemical entity.

Meanwhile, analysts at Roth Capital recently reiterated their Buy rating and $10.30 price target for shares of Neptune based on the revenue growth potential for the multiple krill oil initiatives. That banking firm believes Neptune warrants a higher valuation after seeing the growth and increasing demand for Neptune Krill Oil (NKO) in several territories, a strong IP position, and a key potential catalyst with clinical data read-out later this year from subsidiary Acasti Pharma's (TSX.V:APO) program for CaPreĀ® for the treatment of Hypertriglyceridemia.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus